Aileron Therapeutics Inc (ALRN) Shares Bought by Millennium Management LLC

Millennium Management LLC lifted its holdings in shares of Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% during the second quarter, Holdings Channel reports. The fund owned 123,658 shares of the company’s stock after acquiring an additional 105,073 shares during the period. Millennium Management LLC’s holdings in Aileron Therapeutics were worth $670,000 as of its most recent SEC filing.

Separately, Paloma Partners Management Co purchased a new stake in shares of Aileron Therapeutics during the second quarter worth about $140,000. Hedge funds and other institutional investors own 6.05% of the company’s stock.

A number of equities research analysts have recently weighed in on the company. ValuEngine upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Zacks Investment Research lowered Aileron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 7th.

In other news, major shareholder Bioventures Ltd Novartis sold 20,388 shares of the business’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $2.30, for a total transaction of $46,892.40. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold 51,046 shares of company stock worth $114,236 in the last 90 days. Insiders own 16.10% of the company’s stock.

Shares of ALRN stock opened at $2.13 on Friday. Aileron Therapeutics Inc has a fifty-two week low of $1.75 and a fifty-two week high of $12.96. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.10.

Aileron Therapeutics (NASDAQ:ALRN) last issued its quarterly earnings results on Wednesday, November 7th. The company reported ($0.50) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.58) by $0.08. As a group, sell-side analysts expect that Aileron Therapeutics Inc will post -2.34 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by WKRB News and is the property of of WKRB News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at

Aileron Therapeutics Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

See Also: Do Tariffs Work?

Want to see what other hedge funds are holding ALRN? Visit to get the latest 13F filings and insider trades for Aileron Therapeutics Inc (NASDAQ:ALRN).

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply